One Step at a Time: Applying the Latest Data About Obesity Identification and Management to Real-World Practice—Obesity Series Podcast 1

Important: After listening to the podcast, you will need to visit myCME to complete the post-assessment and evaluation and to claim your credits and certificate for this activity. Please go to www.mycme.com/obesity1 on any browser to complete the activity.

Despite widespread awareness of the potential long-term health consequences of obesity, this chronic disease is not often managed with the determination and urgency that it requires. Poor health outcomes among obese individuals are often exacerbated by weight-related stigma in healthcare settings, as well as lack of knowledge about the safety and efficacy of novel therapeutic options.

This audio activity discusses the importance of early and sustained interventions for patients with obesity, as well as updated guidelines for identification and long-term management. The expert faculty review common obesity comorbidities as well as novel strategies to help patients overcome the metabolic adaptations that make it challenging to keep weight off with lifestyle interventions alone.

This activity is designed for primary care providers (MDs/DOs, PAs, NPs), endocrinologists, cardiologists, dieticians/nutritionist, pharmacists, and other members of the multidisciplinary obesity care team.

This activity is supported by an educational grant from Novo Nordisk.

At the conclusion of this activity, participants should be better able to:

• Describe the underlying pathophysiology of obesity and metabolic adaptations to weight loss
• Apply the most recent evidence-based guidelines for the identification and individualized treatment of obesity in adults and other populations

Faculty

Deepak L. Bhatt, MD, MPH
Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart & Vascular Center
Professor of Medicine
Harvard Medical School
Boston, MA

Dr. Bhatt has received researching funding from Abbott, Afimmune Limited, Amarin Pharma, Inc., Amgen Inc., AstraZeneca, Bayer, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Cardax Inc., CellProthera, Cereno Scientific, Chiesi USA, Inc., CSL Behring LLC, Eisai, Inc., Eli Lilly and Company, Ethicon Inc., Faraday Pharmaceuticals, Ferring Pharmaceuticals Inc., Forest Laboratories Inc., Fractyl Health, Inc., Garmin International, Inc., HLS Therapeutics, Inc., Idorsia Pharmaceuticals Ltd., Ironwood Pharmaceuticals, Inc., Ischemix, Inc., Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Medtronic PLC, MyoKardia Inc., NirvaMed, Inc., Novartis Pharmaceuticals Corp., Novo Nordisk, Owkin, Inc., Pfizer Inc., PhaseBio Pharmaceuticals, PLx Pharma Inc., Regeneron Pharmaceuticals, Inc., Roche Diagnostics Corp. (F. Hoffman-La Roche Ltd), Sanofi, Stasys Medical, Synaptic, The Medicines Company, and 89bio, Inc.

Robert F. Kushner, MD, MS, FACP, DABOM
Professor, Departments of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
Director, Center for Lifestyle Medicine, Northwestern Medicine
Chicago, IL

Dr. Kushner is on the advisory board of Novo Nordisk and WW International, Inc., is a consultant for Pfizer Inc. and Altimmune, and has received research funding from Epitomee Medical.

All of the relevant financial relationships listed for these individuals has been mitigated.